Barclays Downgrades Cellectis to Underweight, Lowers Price Target to $1.3

Barclays analyst Lukas Shumway has downgraded Cellectis (NASDAQ: CLLS) from Overweight to Underweight. The price target for the stock has been reduced significantly from $9 to $1.3.